Document is current

Article History

Received: 7 November 2019

Accepted: 9 May 2020

First Online: 1 June 2020

Ethics approval and consent to participate

: The study protocol was approved by the Institutional Review Board at Tufts Medical Center (ID: 7745). Included patients signed informed consent for usage of their data in scientific research.

: Not applicable.

: The authors declare that they have no competing interests relevant to this study, and their detailed financial disclosure: <b>OS:</b> None; <b>NM:</b> None<b>; CB</b>: Consultant, Genentech, Speaker, Carl Zeiss Meditec, Novartis; <b>AI</b>: Speaker, Topcon Medical Systems, Inc., Nidek Medical Products, Inc.; <b>KL:</b> None; EK: none; <b>SM:</b> None; <b>A.YA</b>: None; <b>MA</b>: None; <b>AW:</b> None; <b>JD:</b> Consultant and Financial Support, Carl Zeiss Meditec, Inc., Optovue, Inc., Novartis Pharma AG., and Roche; <b>NW:</b> Financial Support, Macula Vision Research Foundation, Topcon Medical Systems, Inc., Nidek Medical Products, Inc., and Carl Zeiss Meditec, Inc., Consultant, Optovue, Inc., Regeneron, and Genentech.